Monopar Therapeutics - FORM 10-K - EX-10.16 - CANCER RESEARCH UK LETTER DATED MARCH 21, 2018 - March 26, 2018

Attached files

file filename
10-K - MONOPAR THERAPEUTICS INC. - Monopar Therapeuticsmnpr_form10k.htm
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - Monopar Therapeuticsexhibit_32-1.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeuticsexhibit_31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeuticsexhibit_31-1.htm
EX-14 - CODE OF BUSINESS CONDUCT AND ETHICS - Monopar Therapeuticsexhibit_14.htm
EX-11 - STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS - Monopar Therapeuticsexhibit_11.htm
EX-10.15 - TSUCHIMOTO EMPLOYMENT AGREEMENT AMENDMENT ONE - Monopar Therapeuticsexhibit_10-15.htm
EX-10.14 - PRX CONSULTING AGREEMENT 2018 - Monopar Therapeuticsexhibit_10-14.htm
EX-10.13 - ANDERSON EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-13.htm
EX-10.12 - PRX CONSULTING AGREEMENT 2017 - Monopar Therapeuticsexhibit_10-12.htm
EX-10.11 - MAZAR EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-11.htm
EX-10.10 - MAZAR CONSULTING AGREEMENT - Monopar Therapeuticsexhibit_10-10.htm
EX-10.9 - TSUCHIMOTO EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-9.htm
EX-10.8 - TSUCHIMOTO CONSULTING AGREEMENT - Monopar Therapeuticsexhibit_10-8.htm
EX-10.7 - ROBINSON EMPLOYMENT AGREEMENT AMENDED AND RESTATED - Monopar Therapeuticsexhibit_10-7.htm
EX-10.6 - ROBINSON EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-6.htm
EX-10.5 - MONOPAR THERAPEUTICS INC. 2016 STOCK INCENTIVE PLAN - Monopar Therapeuticsexhibit_10-5.htm
EX-10.4 - TACTICGEM CONTRIBUTION AGREEMENT - Monopar Therapeuticsexhibit_10-4.htm
EX-10.3 - ONXEO OPTION AND LICENSE AGREEMENT - Monopar Therapeuticsexhibit_10-3.htm
EX-10.2 - XOMA LICENSE AGREEMENT - Monopar Therapeuticsexhibit_10-2.htm
EX-10.1 - CANCER RESEARCH UK CTOA - Monopar Therapeuticsexhibit_10-1.htm
EX-3.2 - AMENDED AND RESTATE BYLAWS - Monopar Therapeuticsexhibit_3-2.htm
EX-3.1 - SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Monopar Therapeuticsexhibit_3-1.htm
 
 
 
 
 
 
 
 
 
          
 
 
 
Chandler Robinson Chief Executive Officer
Monopar Therapeutics LLC 598 Rockefeller Road
Lake Forest, IL USA 60045
 
 
 
 
Cancer Research UK
 
Angel Building 407 St John Street London EClV 4AD United Kingdom
 
020 7242 0200
 
cruk.org
 
 
 
2ist March 2018
 
 
 
 
 
Dear Chandler,
 
 
 
 
Clinical Tri.al and Option Agreement between Monopar Therapeutics LLC, Cancer Research UK and Cancer Research Technology Limited dated 15th May 2015 ("the Agreement")
 
 
 
As part of a recent portfolio reprioritisation, Cancer Research UK and Cancer Research Technology have decided to close the project Which is the subject of the Agreement. We will be working with Monopar Therapeutics over the coming months to formalise the arrangements necessary to effect termination of the Agreement.
 
 
Yours faithfully,
 
 
 
 
 /s/ Nigel Blackburn
Nigel Blackburn
 
Director of Drug Development CRUK Centre for Drug Development
 
 
 
 
 
 
 
 
Patron Her Majesty The Queen
 
Presidents HRH The Duke of Gloucester KG GCVO and HRH Princess Alexandra, the Hon Lady Ogilvy KG GCVO Chief Executive Sir Harpal S Kumar
Regist ered Charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103)
 
Regi stered Company limited by guarantee in England and Wales (4325234) and registered rn the Isle of Man (5713F) Registered Address Angel Building, 407 St John Street, London EC1V· 4AD
 

Monopar Therapeutics Reports